Literature DB >> 459006

The incidence of bladder cancer after cyclophosphamide therapy.

W V Fairchild, C R Spence, H D Solomon, M P Gangai.   

Abstract

The records of 19,082 patients with non-uroepithelial cancers were reviewed to determine the incidence of de novo bladder cancer in patients treated with cyclophosphamide versus patients not treated with this drug. A 9-fold increased incidence of bladder cancer was found in the cyclophosphamide-treated group.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 459006     DOI： 10.1016/s0022-5347(17)56306-5

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


  21 in total

Review 1.  Churg-Strauss syndrome.

Authors:  M Conron; H L Beynon
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

2.  Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide?

Authors:  B Hellmich; I Kausch; C Doehn; D Jocham; K Holl-Ulrich; W L Gross
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

Review 3.  Cyclophosphamide toxicity. Characterising and avoiding the problem.

Authors:  L H Fraiser; S Kanekal; J P Kehrer
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

4.  Diagnostically challenging cases: what are atypia and dysplasia?

Authors:  Joseph Sanfrancesco; J Stephen Jones; Donna E Hansel
Journal:  Urol Clin North Am       Date:  2013-02-26       Impact factor: 2.241

Review 5.  The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG).

Authors:  Albert Font; Raquel Luque; José Carlos Villa; Montse Domenech; Sergio Vázquez; Enrique Gallardo; Juan Antonio Virizuela; Carmen Beato; Rafael Morales-Barrera; Antoni Gelabert; Sonia Maciá; Javier Puente; Gustavo Rubio; Xavier Maldonado; Begoña Perez-Valderrama; Alvaro Pinto; Ovidio Fernández Calvo; Enrique Grande; Javier Garde-Noguera; Eva Fernández-Parra; José Ángel Arranz
Journal:  Target Oncol       Date:  2019-02       Impact factor: 4.493

6.  Hemorrhagic cystitis: A challenge to the urologist.

Authors:  R Manikandan; Santosh Kumar; Lalgudi N Dorairajan
Journal:  Indian J Urol       Date:  2010-04

7.  Bladder carcinoma following cyclophosphamide therapy. A case report.

Authors:  H Kiesswetter; N Baloch; J Flamm
Journal:  Int Urol Nephrol       Date:  1985       Impact factor: 2.370

Review 8.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.

Authors:  John H Kempen; Sapna Gangaputra; Ebenezer Daniel; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Kathy J Helzlsouer
Journal:  Am J Ophthalmol       Date:  2008-06-25       Impact factor: 5.258

10.  Flow-cytophotometric studies on urine sediments of patients treated with anti-cancer-drugs.

Authors:  H W Schwabe; H D Adolphs; J Hartlapp
Journal:  Urol Res       Date:  1983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.